About the Authors

Chandrajit P. Raut

Contributed equally to this work with: Chandrajit P. Raut, Yves Boucher, Dan G. Duda

craut@partners.org

Affiliations Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Yves Boucher

Contributed equally to this work with: Chandrajit P. Raut, Yves Boucher, Dan G. Duda

Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Dan G. Duda

Contributed equally to this work with: Chandrajit P. Raut, Yves Boucher, Dan G. Duda

Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Jeffrey A. Morgan

Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Richard Quek

Current address: National Cancer Centre Singapore, Singapore, Singapore

Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Marek Ancukiewicz

Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Johanna Lahdenranta

Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

J. Paul Eder

Current address: Since the study: AstraZeneca PLC, Boston, Massachusetts, United States of America

Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

George D. Demetri

These authors also contributed equally to this work.

Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Rakesh K. Jain

These authors also contributed equally to this work.

Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Competing Interests

Chandrajit P. Raut is a Novartis - Honorarium. Johanna Lahdenranta has an employment/leadership position at Merrimack Pharmaceuticals. J. Paul Eder is currently employed at AstraZeneca PLC. George D. Demetri is a Consultant for Novartis, Pfizer, Ariad, Johnson & Johnson, Genentech, Infinity Pharmaceuticals, ZioPharm, Alnylam, Idera, Momenta Pharma, EMD-Serono, Glaxo Smith Kline, Amgen, Daiichi-Sankyo, ArQule, Enzon, Millenium/Takeda, PamGene (no compensation), Plexxikon, N-of-One (no compensation), Champions Biotechnology, and Kolltan Pharmaceuticals; on the Scientific Advisory Board of ZioPharm, PamGene, Plexxikon, N-of-One, Kolltan Pharmaceuticals (chair); on the Medical Advisory Board at Kolltan Pharmaceuticals (chair); an Honorarium at Novartis and Pfizer; provides research support (to Dana-Farber Cancer Institute for clinical trial) at Novartis, Pfizer, Ariad, Johnson & Johnson, Bristol-Myers Squib, Infinity Pharmaceuticals, and Daiichi-Sankyo; and has equity (minor stake, non-public) at PamGene, Plexxikon, N-of-One, Champions Biotechnology, and Kolltan Pharmaceuticals. Rakesh K. Jain has a Consultant/advisory role at Millenium, Dyax, AstraZeneca, Regeneron, Astellas-Fibrogen, MorphoSys AG, Genzyme, SynDevRx, and Noxxon; is Honoraria at Pfizer and Genzyme (honoraria for lecture); provides research funding/contracted research at Dyax, AstraZeneca and MedImmune; and has ownership interest in SynDevRx. There are no patents or products in development or marketed products to declare. This does not alter the authors′ adherence to all the PLoS ONE policies on sharing data and materials. Yves Boucher, Dan G. Duda, Jeffrey A. Morgan, Richard Quek and Marek Ancukiewicz declare no competing interest.

Author Contributions

Conceived and designed the experiments: CPR YB DGD JAM JPE GDD RKJ. Performed the experiments: CPR YB DGD MA JL JPE RKJ. Analyzed the data: CPR YB DGD JAM RQ MA JL GDD RKJ. Contributed reagents/materials/analysis tools: CPR YB DGD JAM RQ MA JL JPE GDD RKJ. Wrote the paper: CPR YB DGD MA GDD RKJ.